Novoheart Announces Successful Completion of Second Commercial Contract with Global Pharmaceutical Company

Novoheart (TSXV:NVH) is pleased to announce the successful completion of a second commercial contract with a major global pharma partner. The second contract was initiated after a successful initial collaboration that validated the drug screening capabilities of Novoheart’s proprietary MyHeart™ Platform.
As quoted in the press release:

“This is a significant upgrade for drug discovery, because previous genetic mouse models cannot reproduce certain key features of this human condition,” said Novoheart CEO Ronald Li.
Under the agreement, Novoheart has retained ownership of intellectual property generated from the project. A joint scientific report is currently being finalized by both parties, and will be submitted for publication in a peer-reviewed scientific journal.

Click here to read the full press release.